- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00063752
Safety Study of PI-0824 to Treat Pemphigus Vulgaris
June 23, 2005 updated by: Peptimmune
An Open-Label, Dose-Escalation, Phase I Clinical Study to Assess the Safety of PI-0824 in Patient With Pemphigus Vulgaris Requiring Daily Corticosteroid Therapy
The purpose of this study is to determine if the use of PI-0824 in patients with Pemphigus vulgaris is safe.
Study Overview
Detailed Description
Pemphigus vulgaris (PV) is an autoimmune disease affecting approximately 40,000 people worldwide.
People with PV produce antibodies that attack the cells of the skin, resulting in blisters which, if left untreated, can lead to devastating infections and discomfort.
Currently, most doctors who treat patients with PV will prescribe high-dose steroids and drugs that suppress the immune system in an effort to decrease the production of these antibodies.
Unfortunately these medications are associated with serious and difficult side effects that often result in the discontinuation of their use.
Peptimmune, Inc. has developed a new therapy for the treatment of PV, PI-0824.
The goal of this therapy is to reduce the production of antibodies that cause PV blisters by acting only on the disease causing components of the immune system.
It is hoped that use of PI-0824 will reduce or potentially eliminate the need for high dose steroids and drugs that suppress the immune system.
Study Type
Interventional
Enrollment
15
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
San Francisco, California, United States, 94107
- University of California San Francisco
-
-
Maryland
-
Baltimore, Maryland, United States, 21205
- Johns Hopkins School of Medicine
-
-
Massachusetts
-
Salisbury, Massachusetts, United States, 01952
- East Coast Clinical Research
-
-
New York
-
East Setauket, New York, United States, 11733
- Stony Brook Dermatology Associates
-
New Hyde Park, New York, United States, 11040
- Long Island Jewish Medical Center
-
New York, New York, United States, 10016
- NYU School of Medicine
-
-
Ohio
-
Cleveland, Ohio, United States, 44106
- Case Western Reserve University
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- University of Pennsylvania
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Currently experiencing a stable disease course and medication regimen.
Currently taking daily corticosteroid therapy for PV.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Masking: None (Open Label)
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2003
Study Completion
March 1, 2005
Study Registration Dates
First Submitted
July 3, 2003
First Submitted That Met QC Criteria
July 7, 2003
First Posted (Estimate)
July 8, 2003
Study Record Updates
Last Update Posted (Estimate)
June 24, 2005
Last Update Submitted That Met QC Criteria
June 23, 2005
Last Verified
April 1, 2005
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PI-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pemphigus Vulgaris
-
Cabaletta BioRecruitingMucosal -Dominant Pemphigus VulgarisUnited States
-
Cairo UniversityCompletedOral Pemphigus VulgarisEgypt
-
Hoffmann-La RocheAspreva PharmaceuticalsCompletedPemphigus Vulgaris (PV)Turkey, Switzerland, United States, Germany, United Kingdom, Ukraine, Israel, Canada
-
argenxCompletedPemphigus Vulgaris | Pemphigus FoliaceusUnited States, Australia, Bulgaria, China, France, Georgia, Germany, Greece, Hungary, India, Israel, Italy, Japan, Poland, Romania, Russian Federation, Serbia, Spain, Turkey, Ukraine, United Kingdom
-
National Institute of Allergy and Infectious Diseases...Rho Federal Systems Division, Inc.; Autoimmunity Centers of ExcellenceTerminatedPemphigus Vulgaris | Pemphigus FoliaceusUnited States
-
argenxCompletedPemphigus Vulgaris | Pemphigus FoliaceusGermany, Hungary, Israel, Italy, Ukraine
-
argenxActive, not recruitingPemphigus Vulgaris | Pemphigus FoliaceusUnited States, Germany, Italy, Australia, Bulgaria, China, France, Georgia, Greece, Hungary, India, Israel, Japan, Poland, Romania, Russian Federation, Serbia, Spain, Turkey, Ukraine, United Kingdom
-
Assistance Publique - Hôpitaux de ParisInstitut National de la Santé Et de la Recherche Médicale, FranceUnknownPemphigus Vulgaris | Pemphigus FoliaceusFrance
-
Alexion PharmaceuticalsTerminatedPemphigus | Pemphigus Vulgaris | Pemphigus FoliaceusUnited States
-
Principia Biopharma, a Sanofi CompanyPrincipia Biopharma Australia Pty Ltd.CompletedPemphigus VulgarisIsrael, Australia, Greece, Croatia, France
Clinical Trials on PI-0824
-
University Tunis El ManarUnknown
-
Peking University Third HospitalCompletedIsthmic SpondylolisthesisChina
-
Spero TherapeuticsCovanceCompleted
-
Spero TherapeuticsCompleted
-
Spero TherapeuticsClinartisCompleted
-
Cellxpert Biotechnology Corp.Medigen Biotechnology CorporationCompleted
-
Cellxpert Biotechnology Corp.Medigen Biotechnology CorporationCompleted
-
Oslo University HospitalCompleted
-
AmgenCompleted
-
Life Molecular Imaging LtdRecruiting